PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS

被引：0
作者：
Khan, Muhammad [1 ]
机构：
[1] DOW Univ Hosp, Karachi, Pakistan
来源：
TRANSPLANT INTERNATIONAL | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
MP077
引用
收藏
页码：295 / 295
页数：1
相关论文
共 50 条
  • [31] Oral valganciclovir prophylaxis in kidney transplant recipients
    Manuel, O.
    Fellay, J.
    Venetz, J-P.
    Sturzenegger, N.
    Meylan, R.
    Pascual, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2006, 10 : S16 - S16
  • [32] Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients
    Lopez-Medrano, F.
    Rueda, B.
    Lizasoain, M.
    Juan, R. San
    Folgueira, D.
    Andres, A.
    Morales, J. M.
    Jimenez, C.
    Meneu, J. C.
    Aguado, J. M.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (05) : 400 - 404
  • [33] Efficacy and safety of valganciclovir in prophylaxis of cytomegalovirus disease in renal transplant recipients.
    Gabardi, S
    Powelson, J
    Baroletti, SA
    Cina, JL
    Goggins, WC
    PHARMACOTHERAPY, 2003, 23 (03): : 412 - 413
  • [34] Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients
    Vila, A
    Guirado, LL
    Balius, A
    Díaz, M
    Baró, E
    Olaya, M
    Andrade, M
    Agraz, I
    Solá, R
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (06) : 2335 - 2336
  • [35] Universal Prophylaxis with Oral Valganciclovir Significantly Reduces First Year CMV Disease in Kidney Transplant Recipients
    Wu, M. -J.
    Tu, P. -T.
    TRANSPLANTATION, 2012, 94 (10) : 531 - 531
  • [36] Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients
    Luan, F. L.
    Chopra, P.
    Park, J.
    Norman, S.
    Cibrik, D.
    Ojo, A.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (10) : 3673 - 3675
  • [37] Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection
    Veceric-Haler, Zeljka
    Bizjak, Bostjan
    Romozi, Karmen
    Arnol, Miha
    CLINICAL NEPHROLOGY, 2017, 88 : S126 - S130
  • [38] EXTENDING VALGANCICLOVIR PROPHYLAXIS IN KIDNEY TRANSPLANT RECIPIENTS IS ASSOCIATED WITH LOWER INCIDENCE OF CYTOMEGALOVIRUS INFECTION
    Bizjak, Bostjan
    Veceric-Haler, Zeljka
    Romozi, Karmen
    Arnol, Miha
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 407 - 407
  • [39] Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients
    Khoury, J. A.
    Storcha, G. A.
    Bohl, D. L.
    Schuessler, R. M.
    Torrence, S. M.
    Lockwood, M.
    Gaudreault-Keener, M.
    Koch, M. J.
    Miller, B. W.
    Hardinger, K. L.
    Schnitzler, M. A.
    Brennan, D. C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (09) : 2134 - 2143
  • [40] Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts
    Singh, Nina
    Wannstedt, Cheryl
    Keyes, Lois
    Mayher, Debra
    Tickerhoof, Lisa
    Akoad, Mohamed
    Wagener, Marilyn M.
    Cacciarelli, Thomas V.
    LIVER TRANSPLANTATION, 2008, 14 (02) : 240 - 244
12345